Facebook Twitter LinkedIn Google Plus RSS

PTC completes $60 million financing round

By ,

PTC Therapeutics Inc., of South Plainfield, on Thursday announced the completion of a $60 million round of financing, led by Brookside Capital Partners Fund L.P.

According to an announcement from PTC, proceeds from the financing will support continued development of Ataluren, a treatment for patients with muscular dystrophy and cystic fibrosis. The drug is in phase 3 trials.

Write to the Editorial Department at editorial@njbiz.com

Leave a Comment


Please note: All comments will be reviewed and may take up to 24 hours to appear on the site.

Post Comment
View Comment Policy


Subscribe to Our Newsletters!
Click Here to Subscribe for Free Now!